SCHEMBL1067959

SCHEMBL1067959

CCCCOC(=O)C(c1ccc(CBr)cc1)C(C)CC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.57
CHRM4 P08173 2/20 0.57
CHRM1 P11229 2/20 0.57
CHRM3 P20309 2/20 0.57
CYP2D6 P10635 2/20 0.47
CHRM5 P08912 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
TSHR P16473 4/20 0.38
TDP1 Q9NUW8 3/20 0.38
MAPK1 P28482 3/20 0.36
LMNA P02545 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C19 P33261 2/20 0.36
ESR1 P03372 2/20 0.36
NR1H2 P55055 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068900 0.85 CHRM2 (0.58) CHRM2CHRM4CHRM1CHRM3CYP2D6
SCHEMBL3702175 0.80 CHRM2 (0.43) CHRM2CHRM4CHRM1CHRM3CYP2D6
SCHEMBL518030 0.78 CHRM2 (0.43) CHRM2CHRM4CHRM1CHRM3CYP2D6
SCHEMBL1125265 0.74 PTGS2 (0.47) TSHRLMNAESR1CYP2C9ALDH1A1
SCHEMBL6511139 0.72 ESR1 (0.68) CHRM2CHRM1CYP2D6L3MBTL1SMN1; SMN2
SCHEMBL3697239 0.72 CHRM2 (0.34) CHRM2CHRM4CHRM1CHRM3CYP2D6
SCHEMBL517391 0.71 CYP4F2 (0.39) CHRM2CHRM4CHRM1CHRM3L3MBTL1
SCHEMBL5076559 0.71 ELANE (0.46) CYP2D6L3MBTL1SMN1; SMN2TSHRTDP1
SCHEMBL3701806 0.69 ESR1 (0.34) CHRM2CHRM4CHRM1CHRM3CYP2D6
SCHEMBL8984189 0.69 KMT2A (0.49) L3MBTL1SMN1; SMN2NPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268625-A1 OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF Bayer Schering Pharma Aktiengesellschaft (DE) 2011-01-05 EP disclosed